Skip to main content

Month: July 2020

エマウスライフサイエンス社がEndariを用いた憩室症治療のライセンス供与についてパートナー・インターナショナル社との契約を発表

カリフォルニア州トーランス市, July 17, 2020 (GLOBE NEWSWIRE) — 鎌状赤血球症治療をリードするエマウスライフサイエンス社(OTCQB: EMMA)は、同社の処方グレードL-グルタミン経口粉末(PGLG)を憩室症治療に利用するためのライセンス供与について、パートナー・インターナショナル社と契約したことを発表した。これは、FDA(米国食品医薬品局)及びイスラエル保健省によって5歳以上の小児患者及び成人の鎌状赤血球症の急性合併症を軽減する医薬品として承認されているEndariと同じ有効医薬品成分です。憩室症は米国を始めとする諸国において成人に広く存在する胃腸の病気で、無症状の患者も多く存在します。憩室症はときに憩室炎へと進行することがあり、入院や手術を必要とするほど悪化する場合もあります。Endariが、憩室症の進行を遅らせたり改善したりする効果が示唆されている限られた臨床結果に基づいて、エマウスライフサイエンス社は2019年4月に複数の研究施設で10~15名の患者にPGLG経口粉末を使用し大腸憩室の数と大きさの変化を測定し安全性を評価するパイロット/第一相臨床治験を開始しました。この治験の最初の被験者に対する予備的な中間評価では、継続的に良好な結果が示唆されています。この治験は現在進行中ではありますが、同社はこれまでに得られたデータを基に、FDA505(b)(2)に基づく短縮された第三相治験に進む予定です。エマウスライフサイエンス社の会長兼最高経営責任者であり、医学博士及び公衆衛生学修士である新原豊は、次のように述べています。「私たちは、処方グレードL-グルタミンを憩室症に用いる潜在的な治療法についてパートナー・インターナショナル社と契約し、ライセンス供与等について共に働けることを大変嬉しく思います。私の30年に渡る臨床経験の中で、この病気の進行を改善する治療法を観察または聞いたのはこれが初めてのことです。私たちはパートナー・インターナショナル社が製薬業界においてユニークな経験とコネクションを持っていることを高く評価しており、今回の提携によって多くの方々と双方に有益なコラボレーションが行われることを期待しています。」パートナー・インターナショナル社の社長兼最高経営責任者であるJoanne...

Continue reading

엠마우스생명과학 게실증에 대한 엔다리 아웃 라이센싱 주도를 위하여 파트너 인터내셔널과 계약 체결

캘리포니아주 토랜스, July 17, 2020 (GLOBE NEWSWIRE) — 겸상적혈구질환 치료의 선두주자인 Emmaus Life Sciences, 엠마우스생명과학, (“엠마우스”, OTCQB: EMMA)은 게실증 치료에 사용되는 엠마우스의 처방전 등급 L-글루타민 경구용 분말의 아웃 라이센싱 활동을 리드하기 위하여 파트너 인터내셔널과 계약을 체결하게 되었음을 기쁘게 발표하다. 이것은 5세 이상 소아 및 성인환자의 겸상적혈구질환 합병증을 감소시키기 위하여 미국 FDA 및 이스라엘 보건부에서 승인된 엔다리의 활성제약성분과 동일하다.게실증은 종종 미국과 다른 지역의 성인인구의 상당한 영역에 영향을 미치는 무증상 위장 질환이다. 때로는 입원이 필요하고 외과적인 수술이 필요한 위장질환인 게실염으로 진행될 수 있다. 엔다리가 게실증의 진행을 억제하고 역전시킬 수 있음을 암시하는 제한된 임상결과에 기초하여 2019년 04월 엠마우스는 처방전 등급 L-글루타민 경구용 분말의 시범/임상1상 연구를 여러 임상연구 사이트에서 10-15명의 환자들을 대상으로 결장 게실의 수와 크기의 변화 및 안전성 평가 검증을 시작하였다. 임상연구에서 초기 환자들의 예비중간평가는 지속적인 긍정적 결과를 나타냈다. 임상연구는 진행 중이지만 지금까지 얻은 데이터에 근거하여 엠마우스는 미국 FDA의 단축된 505(b)(2) 규제경로 하에 임상3상 연구를 수행할 계획이다.엠마우스의 회장이자 최고경영자인 유타카 니이하라 의학박사는 “우리는 게실증의 잠재적 치료제로서의 처방전 등급 L-글루타민 경구용 분말에 대한 라이센싱 및 협력 기회를 모색하기 위해 파트너 인터내셔널과 같이 일하게 되어 매우 기쁩니다. 저의 30년 임상...

Continue reading

Dealnet featured in Amazon AI Webinar

TORONTO, July 16, 2020 (GLOBE NEWSWIRE) — Dealnet Capital Corp. (“Dealnet” or the “Company”) (TSX VENTURE: DLS) announces the release of an Amazon webinar on Dealnet’s use of Amazon AI Services. Dealnet is leveraging Amazon’s suite of AI tools to reduce the time spent validating customer documents and processing their credit applications.The entire webinar can be viewed at https://www.youtube.com/watch?v=jNUp1SO_0YU&feature=youtu.be or relevant excerpts can be viewed on Dealnet’s website at https://www.dealnetcapital.com/2020-aws/“Amazon’s AI tools have allowed us to fundamentally change our back office,” said Brent Houlden, Dealnet’s Chief Executive Officer. “These automated processes assist in the scaling of our business margins by eliminating errors, ensuring policy compliance, and reducing costs.” About Dealnet Capital...

Continue reading

BIGG Digital Assets Inc. is First to Announce Routing of Funds from Twitter Hack to Known Exchanges

VANCOUVER, British Columbia, July 16, 2020 (GLOBE NEWSWIRE) — BIGG Digital Assets Inc. (“BIGG” or the “Company”)(CSE: BIGG; OTCQB: BBKCF; WKN: A2PS9W), owner of Blockchain Intelligence Group (“BIG”), a leading developer of Blockchain technology search, risk-scoring and data analytics solutions, is the first to announce routing of funds from yesterday’s Twitter hack to known exchanges.Some of the funds fraudulently obtained yesterday as part of a Twitter scam and hack involving several high profile Twitter accounts, including those of Elon Musk, Barack Obama, Justin Sun, Binance, Coinbase and more, have seemingly been transferred to an address possibly linked to the hack, split and then sent to a few different “Know Your Customer” (KYC) regulated exchanges.Funds (approximately USD$13K~) were noted as having...

Continue reading

Bionano Genomics Data is Essential Part of the First Ever Complete Assembly of a Human X-Chromosome

SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that the first ever complete assembly of a human chromosome utilized its genome imaging technology to assemble the genome correctly and verify the accuracy. In a publication in Nature (Miga, K.H., Koren, S., Rhie, A. et al. Telomere-to-telomere assembly of a complete human X chromosome. Nature (2020). https://doi.org/10.1038/s41586-020-2547-7), an international team led by investigators from the University of California, Santa Cruz and the National Human Genome Research Institute described the assembly of a complete, gap-free build of the human X chromosome, covering telomere to telomere in a single contiguous stretch. While several long-read sequencing technologies generated the majority of the sequence, optical mapping data generated...

Continue reading

Oportun to report second quarter 2020 financial results on Thursday, August 6, 2020

SAN CARLOS, Calif., July 16, 2020 (GLOBE NEWSWIRE) — Oportun Financial Corporation (“Oportun” or the “Company”) (Nasdaq: OPRT) will release financial results for the second quarter 2020 on Thursday, August 6, 2020, after market close. Oportun will host a conference call and earnings webcast to discuss results at 5:00 pm ET / 2:00 pm PT on that day.The dial-in number for the conference call is 877-407-9208 (toll-free) or 201-493-6784 (international). Participants should call in 10 minutes prior to the scheduled start time. A live webcast of the call will be accessible from Oportun’s investor relations website at investor.oportun.com. A replay will be available following the end of the call through Thursday, August 20, 2020, by phone at 844-512-2921 (toll-free) or 412-317-6671 (international), passcode 13706113; a webcast replay will...

Continue reading

The Becker Milk Company Limited: 2020 Annual Financial Results

TORONTO, July 16, 2020 (GLOBE NEWSWIRE) — The Becker Milk Company Limited (the “Company”) (TSX-BEK.B) is pleased to report the results for the year ended April 30, 2020.HIGHLIGHTSTotal revenues for the year ended April 30, 2020 were $3,174,164 compared to $3,143,640 for the same period in 2019;Net operating income for the year was $2,569,034 compared to $2,490,962 in 2019;Net income for the year was $0.46 per share, compared to $0.72 per share in 2019.FINANCIAL HIGHLIGHTSNet operating income for the year ended April 30, 2020 increased $78,072 to $2,569,034 as compared with the previous year, principally as a result of reduced operating expenses.Components of the $476,504 decrease in net income for the year ended April 30, 2020 compared to the year ended April 30, 2019 are:ADJUSTED FUNDS FROM OPERATIONSFor the year ended April 30,...

Continue reading

Martin Midstream Partners L.P. Announces Extension of Early Participation Date, Rights Offering Funding Date, Expiration Time and Settlement Date of Exchange Offer, Cash Tender Offer and Consent Solicitations for Certain Outstanding Notes

KILGORE, Texas, July 16, 2020 (GLOBE NEWSWIRE) — Martin Midstream Partners L.P. (Nasdaq: MMLP) (the “Partnership”) today announced that it and its subsidiary, Martin Midstream Finance Corp. (“FinanceCo” and, together with the Partnership, the “Issuers”), have extended (1) the early participation date with respect to its previously announced exchange offer (the “Exchange Offer”) and cash tender offer (the “Cash Tender Offer”) to exchange or purchase, as applicable, the Issuers’ outstanding 7.25% senior unsecured notes due 2021 (the “Existing Notes”) from 5:00 p.m., New York City time, on July 22, 2020, to 5:00 p.m., New York City time, on July 23, 2020 (the “Early Participation Date”), (2) the rights offering funding date with respect to the previously announced rights offering (the “Rights Offering”) for certain holders of Existing...

Continue reading

Euro Manganese Increases Private Placement to $4 Million

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, July 16, 2020 (GLOBE NEWSWIRE) — Euro Manganese Inc. (TSX-V / ASX: EMN) (the “Company” or “EMN“) is pleased to announce it has increased its previously announced private placement (the “Offering“) to 66,202,210 common shares (each a “Share“) for aggregate gross proceeds of C$4.04 million (A$4.27 million). As previously announced, net proceeds of the Offering will be used by the Company to further progress its Chvaletice Manganese Project in the Czech Republic (the “Project“), including advancing the feasibility study and Environmental Impact Assessment, and for other general corporate purposes.Pursuant to the Offering, the Company now intends to...

Continue reading

Targa Resources Corp. Announces Quarterly Dividends and Timing of Second Quarter 2020 Earnings Webcast

HOUSTON, July 16, 2020 (GLOBE NEWSWIRE) — Targa Resources Corp. (“Targa” or the “Company”) (NYSE: TRGP) announced its quarterly dividend on common shares and its quarterly dividend on Series A preferred shares with respect to the second quarter of 2020.Targa announced today that its board of directors has declared a quarterly cash dividend of $0.10 per common share, or $0.40 per common share on an annualized basis, for the second quarter of 2020. This cash dividend will be paid August 17, 2020 on all outstanding common shares to holders of record as of the close of business on July 31, 2020.Targa also announced today that its board of directors has declared a quarterly cash dividend of $23.75 per Series A preferred share for the second quarter of 2020. This cash dividend will be paid August 14, 2020 on all outstanding Series A preferred...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.